A Computational Model of Oral Transmucosal Carvedilol Delivery by Jarmas, Alison et al.
A Computational Model of Oral Transmucosal Carvedilol 
Delivery 
 
BEE/MAE 4530 
Computer Aided Engineering —Applications to Biomedical Processes 
 
Group 06 
 
Alison Jarmas 
Olivia Ly 
Lauren Tang 
Heming Zhao 
 
  
1 of 31 
 
Table of Contents 
 
1. Executive Summary ................................................................................................................ 3 
2. Introduction to Transmucosal Drug Delivery Modeling ........................................................ 4 
3. Problem Statement and Design Objectives ............................................................................. 6 
4. Schematic ................................................................................................................................ 7 
5. Methods................................................................................................................................... 9 
6. Results ................................................................................................................................... 11 
A. Carvedilol Diffusion in the Tissue Regions ................................................................... 11 
B. Carvedilol in the Bloodstream........................................................................................ 11 
C. Cumulative Release Profiles .......................................................................................... 13 
D. Optimization and Objective Function ............................................................................ 14 
E. Hypothetical Baseline Analysis ..................................................................................... 14 
7. Accuracy Check .................................................................................................................... 16 
8. Sensitivity Analysis of Various Parameters .......................................................................... 18 
9. Conclusions and Design Recommendations ......................................................................... 21 
10. Appendix ............................................................................................................................ 22 
A. Mathematical Statement of the Problem ........................................................................ 22 
B. Solution Strategy ............................................................................................................ 24 
C. Additional Visuals .......................................................................................................... 27 
D. References ...................................................................................................................... 30 
 
  
2 of 31 
 
1. Executive Summary 
 
 In the past few decades, there has been a rapid growth in alternative drug delivery routes. 
The oral cavity has gained attention as an attractive drug delivery site because it enhances drug 
bioavailability, allows for rapid transport to the systemic circulation, and provides a convenient 
delivery route. The buccal mucosa is one of the most common routes for oral drug delivery 
because it is relatively permeable and robust in comparison to other mucosal tissues. The buccal 
mucosa offers a large surface for absorption, allows for prolonged localized therapy, and avoids 
first-pass metabolism effects and degradation in the gastrointestinal environment.  
One potential form of buccal drug therapy currently being investigated is the application 
of bioadhesive polymer patches to the buccal region of the mouth. Direct contact between a 
patch and the buccal mucosa allows a drug concentration gradient to favor diffusion into the 
tissue. Researchers have recently begun to use this innovative method of drug delivery with 
carvedilol, a non-selective β-adrenergic antagonist used to treat heart failure and high blood 
pressure.  
Recent studies have investigated the formulation of bioadhesive patches of carvedilol. 
The goals of the project are to model drug delivery from a biodegradable carvedilol patch 
prepared with the PLGA polymer and optimize carvedilol concentration in the blood. The 
COMSOL Multiphysics 4.3 simulation software was used to model drug diffusion through the 
buccal mucosa and solve the governing equations used in our simulation. Drug diffusion was 
modeled using the species mass transport equation through a two-dimensional cross section 
including the carvedilol patch and surrounding tissue. Saliva flow over the patch and in the 
mucus region was modeled with one-dimensional Navier-Stokes fluid flow equations.  
Concentration and flux profiles over the course of the three hour treatment confirm that 
carvedilol is able to diffuse from the patch and be delivered to the tissue and bloodstream. 
Approximately 100% of the patch is delivered within three hours. We evaluated patch efficiency 
using the concentration in the blood as a fraction of the initial patch concentration. The peak 
carvedilol concentration is reached at 1.8 hours. Drug degradation in the submucosa results in an 
observable reduction in carvedilol concentration in the bloodstream. Our results were validated 
based on cumulative drug release and peak concentration data from in vitro and in vivo studies. 
Since the availability of property data is limited, we performed sensitivity analysis over a range 
of diffusivity values and saliva flow velocities. 
Multiple drugs are currently being evaluated for oral mucosal therapy, but the high costs 
associated with developing these drug delivery systems have limited commercial availability. 
Computational fluid dynamics (CFD) modeling is necessary to determine the ideal parameters 
and properties to maximize drug efficacy and the percentage of drug that leaves the patch in an 
economical and safe method. Our observations will allow carvedilol treatment to be optimized 
by investigating initial drug concentration in the patch and treatment time. This computer model 
could potentially aid the design of clinical trials testing different patch configurations and 
treatment times.  
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2. Introduction to Transmucosal Drug Delivery Modeling 
 
 The optimization of drug delivery is a critical focus of biomedical research. The 
investigation of alternative routes of drug delivery to maximize therapeutic efficacy is expansive, 
involving oral, intravenous, transdermal, inhalation and transmucosal drug delivery systems (Li 
et al, 2013). The latter route of drug administration involves the placement of diffusion-
controlled patches, films or tablets inside the buccal (interior surface of the lips and cheeks), 
sublingual (underneath the tongue) or palatal (soft palate) mucosal regions of the interior oral 
cavity (Venkala et al, 2012).   
Transmucosal drug delivery offers patients a non-invasive method of drug administration 
with potentially more rapid uptake. The buccal mucosal layer offers several advantages and 
constraints as a site of drug delivery. The literature reports that the permeability of the buccal 
mucosa, while less than that of the sublingual mucosa, is between 4 and 4000 times greater than 
that of the skin, suggesting an advantage over transdermal systems developed in previous studies 
(Venkala et al, 2012; Kshirsagar et al, 2012). As a more robust mucosal layer, the buccal region 
is able to withstand the patch application and adhesion. Additionally, the buccal mucosa exhibits 
a low sensitivity to irritants and allergens that may be present in the patch formulation. In the 
oral cavity, however, salivary flow can result in significant flushing of the drug away from the 
site of application (Venkala et al, 2012).       
Transmucosal drug delivery is currently being investigated for a large number of medical 
applications, including pain control, diabetes management, and antibiotic therapy (Kumbria & 
Goomber, 2011). This project will focus on modeling the drug compound carvedilol, an α/β-
adrenergic blocking agent which is used to treat various stages of congestive heart failure (CHF), 
as well as left ventricular dysfunction and hypertension (COREG Tablet, 2013). The mechanism 
of the drug’s efficacy is fairly well-established, as β-blockers have been demonstrated to improve 
the function of the left ventricle of the heart. Mild to moderate dizziness, fatigue and hypotension 
are the most commonly reported adverse side effects of this drug compound (Vanderhoff et al, 
1998). Current iterations of carvedilol therapy involve oral ingestion of tablets, with sequentially 
higher drug content levels of 3.125 mg, 6.25 mg, 12.5 mg and 25 mg as clinically-indicated 
(COREG Tablet, 2013).  
This project will investigate the design of a transmucosal drug delivery system for 
carvedilol across the buccal region of the oral cavity. A computational model will be developed 
to investigate the concentration profile and flux pattern for a transmucosal carvedilol patch. The 
patch design incorporates a biodegradable patch polymer, often supplemented with the adhesive 
biocompatible polymer chitosan (Kaur & Kaur, 2012; Giannola et al, 2013). The therapeutic 
result, in terms of the attained peak blood plasma concentration of the drug, will be investigated 
and compared to animal models and available pharmacokinetic data (Arsenault et al, 2005; 
Nikoli et al, 2013). The effect of degradation of the drug in the blood will also be considered. 
Additionally, the effects of varied conditions and parameters such as the salivary fluid flow 
pattern and the thickness of the mucosal layers (which vary widely between different 
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individuals) will be computed through sensitivity analysis. Finally, this project endeavors to 
provide a design recommendation for an optimized transmucosal carvedilol treatment protocol 
by investigating the maximum cumulative drug release from the patch.   
 The computational model results provided clinical insight in terms of developing more 
effective, consistent treatment protocols. The results of this project could be translated to a 
variety of other long-term therapeutic drug regimens.  
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3. Problem Statement and Design Objectives 
 
The goal of this study was to develop a computational model to investigate and optimize oral 
transmucosal carvedilol delivery.     
 
Specific objectives included: 
- Developing an accurate and realistic model of oral transmucosal carvedilol delivery  
- Modeling the biodegradability of the patch 
- Investigating drug degradation in the submucosal blood  
- Conducting sensitivity analysis to determine the required precision for model input 
parameters 
- Validating the computational model with experimental data for cumulative drug release 
and peak drug concentration in the blood   
- Optimizing the patch efficiency using an objective function  
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4. Schematic 
 
 Figure 1a below shows the regions of the interior oral cavity with this model focusing on 
a patch placed in the buccal region. Figure 1b shows a 2D cross section of the mucus, buccal 
mucosa, and submucosa tissue layers. The drug diffuses from the patch through the buccal 
mucosa and submucosa.  
 
(a) 
 
 (b)            
Figure 1: (a) Buccal Region of the Oral Cavity: The buccal region refers to the inner lining of the cheeks 
and lips. It is composed primarily of epithelial and connective tissue. (b) Structure of the buccal region of 
the oral cavity: The buccal region is composed of three primary layers: mucus, buccal mucosa, and 
submucosa. The buccal mucosa is composed of multiple layers of epithelial tissue. The sub mucosa lies 
beneath the buccal mucosa and consists of blood vessels and nerves.  
Mucus 
Buccal 
mucosa 
Sub mucosa 
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 The patch we are investigating was prepared using poly lactic-co-glycolic acid (PLGA), a 
biodegradable polymer. Figure 2a shows 1D saliva flow over this patch construct. We have 
simplified carvedilol diffusion through the buccal region using a 2D domain shown in Figure 2b. 
We are considering diffusion in the x-direction only and considering diffusion in the y-direction 
to be negligible because of the dimensions of the patch relative to the tissue depth.  
 
 
(a) 
 
(b) 
Figure 2: Schematic of the carvedilol patch and 2D tissue cross section in our model. a) 1D saliva flow 
occurs over the carvedilol patch. b) Carvedilol diffusion occurs through the buccal mucosa and sub 
mucosa regions. Saliva flow is only present in the mucus region, which surrounds the patch. Boundary 
conditions for the governing equations are shown.  
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5. Methods 
 
Buccal carvedilol delivery was simplified and modeled in COMSOL using the mass transport 
equation coupled with fluid flow physics for the saliva flow. Diffusion in the patch, mucus, 
buccal mucosa is modeled by the equation: 
 
𝜕𝜕𝑐𝑐𝐴𝐴
𝜕𝜕𝜕𝜕
+ 𝑢𝑢𝑥𝑥 𝜕𝜕𝑐𝑐𝐴𝐴𝜕𝜕𝑥𝑥 + 𝑢𝑢𝑦𝑦 𝜕𝜕𝑐𝑐𝐴𝐴𝜕𝜕𝑦𝑦 = 𝐷𝐷𝐴𝐴(𝜕𝜕2𝑐𝑐𝐴𝐴𝜕𝜕𝑥𝑥2 + 𝜕𝜕2𝑐𝑐𝐴𝐴𝜕𝜕𝑦𝑦2 )      [Equation 1] 
where cA is the concentration of carvedilol, uy is the saliva velocity, and DA is the diffusivity of 
carvedilol in each region.  
 
In the submucosa, there is degradation of carvedilol which is represented by the first order 
reaction term, RA.  
𝜕𝜕𝑐𝑐𝐴𝐴
𝜕𝜕𝜕𝜕
+ 𝑢𝑢𝑥𝑥 𝜕𝜕𝑐𝑐𝐴𝐴𝜕𝜕𝑥𝑥 + 𝑢𝑢𝑦𝑦 𝜕𝜕𝑐𝑐𝐴𝐴𝜕𝜕𝑦𝑦 = 𝐷𝐷𝐴𝐴 �𝜕𝜕2𝑐𝑐𝐴𝐴𝜕𝜕𝑥𝑥2 + 𝜕𝜕2𝑐𝑐𝐴𝐴𝜕𝜕𝑦𝑦2 � − 𝑅𝑅𝐴𝐴, where 𝑅𝑅𝐴𝐴 = − 𝜆𝜆𝑐𝑐𝐴𝐴 [Equation 2] 
The half-life of carvedilol in the bloodstream is reported to be seven to ten hours (Vanderhoff et 
al, 1998). The rate constant of carvedilol degradation in the blood was approximated using the 
following expression: 
𝜆𝜆 = −𝑙𝑙𝑙𝑙�12�
𝜕𝜕1
2�
= −𝑙𝑙𝑙𝑙�12�
25200 𝑠𝑠𝑠𝑠𝑐𝑐 = 0.000028 𝑠𝑠𝑠𝑠𝑐𝑐−1   [Equation 3] 
In order to determine the effect of saliva flow on drug delivery, a simplified Navier-Stokes 
equation for fluid flow was implemented. We assumed steady state saliva flow and treated the 
inertial and gravity terms as negligible.  
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= + − ∂ ∂ ∂ 
 ∂ ∂ ∂
= + − ∂ ∂ ∂ 
    [Equation 4] 
In modeling the biodegradation of our patch, we assumed a constant rate of change in the patch 
thickness. We used the half-life of PLGA, 3.97 weeks, to calculate the velocity at which the 
patch shrinks (Vishnu, et. al. 2006).  
 
0.0001𝑚𝑚
3.97 𝑤𝑤𝑠𝑠𝑠𝑠𝑤𝑤𝑠𝑠 � 1 𝑤𝑤𝑠𝑠𝑠𝑠𝑤𝑤168 ℎ𝑜𝑜𝑜𝑜𝑜𝑜𝑠𝑠� �1 ℎ𝑜𝑜𝑜𝑜𝑜𝑜3600 𝑠𝑠� = 4.1648 × 10−11 𝑚𝑚𝑠𝑠           [Equation 5] 
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Initial Conditions: 
Initially, there is no carvedilol in the mucus or tissue regions because the drug is contained in the 
patch. The initial concentration of the carvedilol in the patch is found by dividing the mass by the 
volume of the patch. The patch dimensions are 2cm x 2cm x 0.2mm resulting in a patch volume 
of 8 x 10-8 m3. We will consider carvedilol masses of 3.125mg, 31.25 mg, and 312.5 mg with the 
31.25 mg carvedilol patch representing our basis for computation. The following equation was 
used to calculate the initial concentration of carvedilol in the patch region. 
𝐶𝐶0 = 𝑚𝑚𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑉𝑉𝑝𝑝𝑐𝑐𝑝𝑝𝑐𝑐ℎ        [Equation 6] 
Material Properties/Model Input Parameters: 
The diffusivities of carvedilol in saliva, the PLGA patch, buccal mucosa, and submucosa tissue 
were approximated using the following equation: 
𝐷𝐷 = �9.40×10−11�(𝑇𝑇)
𝜇𝜇𝑀𝑀𝑤𝑤
1
3�
 (Saltzman, 2001)   [Equation 7] 
Where T=310.15, Mw = molecular weight of carvedilol, and µ= viscosity of the substance. 
 
This equation is derived from the Stokes-Einstein equation: 
 𝐷𝐷𝐴𝐴 = 𝑤𝑤𝐵𝐵𝑇𝑇6𝜋𝜋µ𝑎𝑎              [Equation 8] 
The Stokes-Einstein equation incorporates the effects of frictional drag and temperature on the 
diffusivity. It is used to predict diffusion coefficients of molecules based on their molecular 
weights (Saltzman 2001). 
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6. Results 
 
 The goal of this study was to develop a computational model to investigate and optimize 
drug delivery from a transmucosal carvedilol patch. The following section details the results 
obtained from the studies performed – diffusion through the tissue layers, degradation in the 
submucosa blood vessels, flux into the blood, and cumulative drug release. 
 
A. Carvedilol Diffusion in the Tissue Regions 
 Using a time step of 300 seconds, we modeled the release of carvedilol out of the patch 
over the course of the three hour treatment. The surface plots show that nearly all of the 
carvedilol leaves the patch within the three hour treatment.  
 
     
Figure 3: Surface plots of buccal carvedilol patch. Carvedilol diffusion from the patch is shown at 0 
seconds, 300 seconds, 5400 seconds (1.5 hrs), and 10800 seconds (3hrs). 
B. Carvedilol in the Bloodstream 
Effect of degradation in the blood 
Carvedilol is degraded in the submucosa; the submucosa was simplified as a uniform 
layer of blood due to the high density of vessels present in this tissue layer. Drug degradation in 
the submucosa was modeled using a first-order reaction term in the mass transport equation. 
Figure 4 shows the effect of degradation on the carvedilol concentration in the bloodstream. We 
evaluated carvedilol concentration at a point in the submucosa near the buccal mucosa and sub 
mucosa boundary. We confirmed that a higher maximum concentration at this point is reached 
without degradation.  
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Figure 4: Effect of degradation on carvedilol concentration in the submucosa. The concentration profiles 
show the effect of degradation on the concentration at a specified point in the submucosa region. 
Flux profile at buccal mucosa/submucosa boundary 
Another objective was to determine the amount of carvedilol entering the submucosa 
blood vessels. First, we calculated the flux of drug into the submucosa. There is a large increase 
in flux at the start of treatment because of the large concentration gradient. As the drug diffuses 
and enters the bloodstream, the flux decreases with time because the concentration gradient 
decreases. 
 
Figure 5: Flux Profile at the submucosa boundary. This figure shows the flux into the submucosa over 
the three hour treatment. 
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C. Cumulative Release Profiles 
In order to determine the amount of drug that accumulates in the blood, we integrated our 
flux over the length of the patch to determine the mass/length of carvedilol entering the blood. 
As shown in Figure 6 below, the entire mass of carvedilol leaves the patch within three hours but 
only about 50% of the drug has entered the bloodstream. The amount of drug carried away by the 
mucus is minimal.  
 
Figure 6: Cumulative drug release from the patch over time. The amount of drug that has left the patch 
and the amount entering the blood are shown. There is a minimal amount of drug carried away from the 
delivery site by saliva flow.   
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D. Optimization and Objective Function  
 In a design problem, there are numerous possible approaches to optimization. For this 
problem statement, the results are intended to be informative for the overall drug delivery 
mechanism via a transmucosal patch rather than the specific treatment with carvedilol. 
Therefore, rather than investigate the specific systemic concentration, we elected to develop an 
objective function which reflects the ‘efficiency’ of the patch in terms of the percentage of the 
initial drug concentration that reaches a particular point in the submucosa at the midpoint of the 
treatment. Maximizing the objective function provided in Figure 7 below represents the most 
efficient patch based on the initial concentration; this objective function was defined from the 
model of a patch of initial mass 3.125 mg. Since this objective function was derived from model 
data, and the model was not run for all possible multiples of the initial concentration, 
interpolation is required.       
   
 -50c - 2000  0 < c < 50ci 
Objective function: J =   -880c + 38,000  50ci < c < 100ci 
          
 
Figure 7. Objective function for optimization of patch ‘efficiency’  
E. Hypothetical Baseline Analysis  
 One of the main limitations we encountered in our model was the slow rate of 
degradation of the patch, given the polymer used in the initial design. Therefore, we conducted a 
baseline analysis of the drug delivery system with a hypothetical polymer demonstrating 
complete 100% degradation during the three hour treatment time. This would be beneficial for 
the patient because it would eliminate the need to remove the adhesive polymer from the interior 
surface of the cheek.   
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The surface plots in Figure 8 below reflect the transient carvedilol transport. As the 
thickness of the patch decreases with biodegradation, the mucus boundary is observed to 
appropriately shift.   
 
 
Figure 8: Surface plots of hypothetical 100% biodegradable patch. As the patch shrinks with time, it is 
replaced by the mucus and saliva flow layer.   
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7. Accuracy Check  
 
Comparison between Cumulative Drug Release Profile and Experimental Studies  
 In order to validate our model, the cumulative drug release from the patch was compared 
to values found in literature. Since buccal carvedilol patches made using PGLA have not been 
well tested, we compared the drug release in our patch to that of studies using carvedilol patches 
containing other polymers such as HPMC and Carbopol. Cumulative drug release in vitro of 
86.26 to 98.32% and 74.63 to 88.02% in vivo within 90 minutes were reported for a HPMC 
polymer patch (Thimmasetty, 2008).  
 In order to calculate the cumulative drug release in COMSOL, we first integrated the flux 
out of the patch over the length of the patch. Using this we were able to find the mass/length of 
drug exiting the patch over the course of treatment. These values were multiplied by the length 
of the patch and divided by the initial mass of carvedilol in the patch. We obtained a cumulative 
drug release profile over time and a plot of the amount of drug entering the blood. As shown in 
Figure 9, nearly 100% of the drug was released in three hours in the three initial carvedilol 
masses tested.  
For the purpose of comparison and validating our studies, it is reasonable to conclude that 
our model produced valid results as the 90% drug release at the midpoint of treatment falls 
within the in vitro range and slightly above the in vivo range. There are many factors that may 
contribute to this difference including the polymer selection and relative masses of carvedilol 
and polymer in the patch. Although there are variations in our patch modeled using PLGA and 
the HPMC polymer tested in the study, our results indicate that the use of a biodegradable patch 
was effective in delivering the drug.  
 
Figure 9: Cumulative Drug Release Profile. This figure shows the cumulative drug release over time 
from our COMSOL model patch containing an initial carvedilol mass of 3.125mg. Experimental data 
shows the cumulative drug release at 1.5 hours from in vitro and in vivo studies.  
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Analysis of Peak Carvedilol Concentration in Blood with Comparison to Experimental Studies  
Another approach to validating this model involved a comparison of the peak (maximum) 
carvedilol concentration in the submucosal/blood region over the duration of the treatment to 
experimental studies in a canine model system (Arsenault et al, 2005). In our model with an 
initial carvedilol mass of 3.125 mg, the maximum blood concentration of 1.4655 kg/m3 was 
reached at 1.83 hours, as shown in Figure 10. 
 
Figure 10: Peak concentration of carvedilol in the blood/submucosa region over time. With an initial 
patch mass of 3.125 mg carvedilol, the peak concentration is reached at 1.8 hours.   
In the canine model developed by Arsenault et al, 175 µg/kg carvedilol was delivered 
intravenously to dogs of an average estimated mass of 25 kg. This resulted in an average drug 
mass of 4.375 mg. The mean peak plasma concentration was reported as 0.77 kg/m3 (Arsenault 
et al, 2005).  
The combination of the canine and COMSOL model results suggest some differences in 
the drug delivery profiles. It is important to consider that the modes of drug delivery differ; the 
canine model involved intravenous delivery, while our solution models transmucosal delivery via 
an oral patch. Nevertheless, this comparison yields two important points. First, the peak 
concentration was reached at approximately the same point in the treatment duration. Second, the 
canine model system was associated with extreme variability, with our peak concentration 
occurring just above the upper extreme of the canine model.  On a unit initial mass basis, the 
transmucosal drug delivery mechanism resulted in a 2.65-fold increase in the calculated 
maximum carvedilol concentrations.  
Overall, the discrepancies between the experimental and computed values can be 
attributed to the many assumptions and approximations made in modeling. The model simplified 
the geometry of the layers of the buccal mucosa and assumed a uniform layer of blood. Since the 
deviations of the model from experimental results are relatively small, it would be in the realm of 
possibilities to conclude that the computed results are valid.  
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8. Sensitivity Analysis of Various Parameters 
 
The three main parameter types evaluated for sensitivity analysis are: 
• Diffusivity of carvedilol in the mucus, patch, buccal mucosa, and submucosa: Since 
all the diffusivity values are approximations, diffusivity values +/- 10% of the value 
used were tested. The saliva was approximated to have material properties similar to 
that of water as there are minimal differences between the two substances. Testing the 
+/- 10% range accounts for differences in properties between individuals.   
• Saliva flow velocity: This value varies from person to person so the +/- 10% range 
was applied to the saliva flow velocity to ensure that our model is more 
representative. 
• Initial carvedilol concentration in the patch: The initial carvedilol concentration was 
increased and decreased by one and two orders of magnitude to assess the effect of 
this model parameter.   
The first component of the sensitivity analysis was to assess the effect of the diffusivity 
in each layer on the model results. Since drug diffusivity values in different tissue layers are very 
difficult to obtain and can vary between individuals, it was important to determine how accurate 
our model parameters must be to ensure a meaningful result. A range approach to sensitivity 
analysis was used, which involved parametric sweeps of the different diffusivity values with the 
actual (approximated) parameter values as well as values + 10% and –10%. The base model 
values for carvedilol diffusivity are 2.1216e-11(patch), 3.9356e-10 (mucus), 5.9000e-11 (buccal 
mucosa) and 9.8390e-10 (blood/submucosa region).  All diffusivity values are reported in m2/s. 
To quantify the results of the sensitivity analysis, the concentration of carvedilol at 5400 sec, the 
midpoint of the treatment time, at a point very near the submucosal boundary (0.002m, 0.11m) 
was used as the point of analysis.  
 
-10%   Do  +10% 
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Figure 11: Sensitivity analysis for diffusivity parameters. This figure indicates that the model is sensitive 
to the diffusivities only in the mucus and blood/submucosal layers.  
The effect of saliva flow velocity on the concentration of carvedilol at a point right 
outside the patch (4.8e-6m, 0.11m) at the midpoint of the treatment time was also assessed for 
sensitivity analysis. The base model value used for saliva flow velocity was 5.0e-6 m/s and a +/-
10% range was tested (4.5e-6 m/s and 5.5e-6 m/s respectively).  
 
Figure 12: Sensitivity analysis for saliva flow velocity. This figure indicates that the model is slightly 
sensitive to velocity in the mucus layer.  
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Finally, the effect of the initial carvedilol concentration in the patch was investigated by 
varying the initial concentration by two orders of magnitude above and below the baseline value 
of 390.625 kg/m3. Since this parameter directly affects the concentration profiles, the sensitivity 
analysis was done with respect to the concentration at the specific point (0.002, 0.11) expressed 
as a percentage of the initial concentration. The results in Figure 13 indicate that increasing the 
concentration by two orders of magnitude has the greatest effect, with other changes in the 
parameter negligible.  
 
 
Figure 13: Sensitivity analysis for initial carvedilol concentration in the patch. This figure indicates that 
larger increases in the order of magnitude of the parameter exhibit a more pronounced effect on the 
carvedilol profile.   
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9. Conclusions and Design Recommendations 
 
This computational model investigated the optimization of carvedilol drug delivery via an 
oral transmucosal patch applied to the buccal region of the interior oral cavity. The analysis 
centered on investigating the effect of degradation of the drug in the blood, determining the 
cumulative drug release profile, and assessing the peak concentration reached in the blood. The 
results of this modeling process are relevant both for this specific application as well as for 
transmucosal drug delivery systems in general. 
Current research in this area involves the development of such patches for animal models. 
This study can provide informative results to aid in the design of targeted clinical trials with 
respect to parameters such as treatment duration and patch efficiency. This reflects the 
advantages of thorough computational modeling in reducing the need for costly and time-
intensive pre-clinical trials.    
A significant aspect of this project was the generation of mass per length plots which were 
used to calculate the amount of drug leaving the patch, the amount of drug accumulating in the 
blood, and the amount of drug carried away from the target delivery site by the mucus and saliva 
flow. While literature suggested that transmucosal drug delivery may be impeded by the flushing 
of drug away from the delivery site by the saliva flow, our model found this effect to be 
negligible for the average saliva velocity.  
An additional component of this project endeavored to optimize the patch efficiency, a 
quantity defined as the percentage of the initial drug concentration at a particular point in the 
submucosal blood at the midpoint of the treatment. Comparing these values for a range of initial 
patch masses indicated that patches with lower initial drug masses were noticeably more 
efficient. Such information would be useful to pharmaceutical companies in designing a patch 
which is both therapeutically and economically efficient.    
A key limitation of this base model was the slow rate at which the patch polymer degraded. 
Therefore, a preliminary analysis was conducted for a hypothetical patch construct that degrades 
completely during the standard treatment time of three hours. This benefits the patient by 
eliminating the need to remove the mucoadhesive patch at the end of the treatment. Therefore, 
the results of this preliminary modeling suggest that future research should focus on the design 
or identification of a biocompatible patch polymer which will degrade at the targeted rate.    
The economic and safety constraints involved in this design process are limited. Patch 
materials must be biocompatible and the peak drug concentration in a patient must not exceed 
safe limits. Suggested areas for expanded research include investigating the effect of non-
uniform salivary flow, determining the effect of individual variations in tissue layer thickness on 
the drug delivery, and developing a rapidly degrading patch.  
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10. Appendix 
A. Mathematical Statement of the Problem 
Governing Equations 
For mass transport: 
𝜕𝜕𝑐𝑐𝐴𝐴
𝜕𝜕𝜕𝜕
+ 𝑢𝑢𝑦𝑦 𝜕𝜕𝑐𝑐𝐴𝐴𝜕𝜕𝜕𝜕 = 𝐷𝐷𝐴𝐴 𝜕𝜕2𝑐𝑐𝑎𝑎𝜕𝜕𝑥𝑥2 − 𝑅𝑅𝐴𝐴 
For fluid flow (saliva):  0 = −𝜕𝜕𝜕𝜕
𝜕𝜕𝜕𝜕
+ 𝜇𝜇 �𝜕𝜕2𝑣𝑣
𝜕𝜕𝜕𝜕2
� 
Boundary Conditions and Initial Values 
A. For mass transport, a no flux boundary condition was set at all outer boundaries. For fluid 
flow, we set the inlet velocity in the mucus layer to the average saliva velocity, 5x10-6 
m/s (Watanabe, 2012). At the other end of the mucus layer, we set the outlet pressure to 
zero. 
B. For initial conditions, we defined an initial concentration in the patch region and set the 
concentration in all other regions to be zero.  
𝐶𝐶0,𝑝𝑝𝑎𝑎𝜕𝜕𝑐𝑐ℎ = 𝑚𝑚𝑐𝑐𝑎𝑎𝑜𝑜𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑙𝑙𝑜𝑜𝑙𝑙𝑉𝑉𝑝𝑝𝑎𝑎𝜕𝜕𝑐𝑐ℎ = 31.25 𝑚𝑚𝑚𝑚8 x 10−8 𝑚𝑚3 = 390.625 𝑘𝑘𝑚𝑚𝑚𝑚3  
Table A1: Material properties and input parameters for mass transfer and fluid flow 
Property Value Unit Reference 
Carvedilol molecular weight  406.5 Da PubChem, 2014 
PLGA molecular weight  150 kDa Lu, 2000 
Initial carvedilol concentration in 
patch 
390.625 kg/m3 N/A 
Initial carvedilol concentration in 
mucus, buccal mucosa, submucosa 
0 kg/m3 N/A 
Average saliva velocity 5x10-6  m/s Watanabe, 2012 
Diffusivity of carvedilol in saliva  3.9356× 10-10 m2/s Datta and Rakesh, 2010 
Diffusivity of carvedilol in patch 2.1216 × 10-11 m2/s Sonjoy, 2011 
Diffusivity of carvedilol in tissue 5.9 × 10-11 m2/s Meyer, 2009 
Diffusivity of carvedilol in blood 9.8390 × 10-10 m2/s Meyer 2009 
Carvedilol viscosity 0.01855 Pa-s Sonjoy 2011 
Saliva density 1002 kg/m3 Mehravaran et. al., 2008 
Saliva viscosity 0.01285 Pa-s Mehravaran et. al., 2008 
Blood density 1060 kg/m3 Datta and Rakesh, 2010 
Blood viscosity 0.001248 Pa-s Klabunde, 2010 
 
Evaluation of diffusivities 
Since diffusivity values for specific drug/polymer combinations are not readily available, 
we calculated the carvedilol diffusivity in our PLGA patch to be 2.1216 x 10-10 m2/s using 
Equation 7 and the appropriate molecular weights shown in Table A1. To evaluate our 
diffusivity value, we compared it to diffusivities of drugs in polymers of similar molecular 
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weight. Table A2 shows several patch/polymer combinations. Our calculated diffusivity value is 
within the range/same order of magnitude of the values found in the literature. The variability in 
the diffusivity values found may be due factors such as pH, hydrophobicity, polarity, and 
temperature.  
 
Table A2: Diffusivity of drug/polymer combinations of similar molecular weight 
Substance Molecular 
Weight (Da) 
Polymer Molecular 
Weight (kDa) 
Diffusivity 
(m2/s) 
Reference 
Hydrocortisone 362  EVA 150 1.18e-11 Kydonieus, 1995 
Buprenophrine 467 PLCL 162 9.98e-10 Koocheki, et. al., 
2011 
Ketotifen 
fumarate  
425 HEMA 130 5.57e-10 Alonso, 2012 
Timolol 
maleate 
432 DMAA 142 6.66e-10 Alonso, 2012 
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B. Solution Strategy 
Solvers 
The COMSOL linear systems solver direct (MUMPS and PARDISO) were used to find 
the complete solution of this model. The problem was a transient model solved from 0 to 10800 
seconds with a time step of 300 seconds. The default values for relative and absolute tolerance, 
0.01 and 0.001, were used. 
 
Mesh Development and Convergence 
We used a structured mesh due to the regular geometry of our model. A finer mesh was 
implemented in the mucus region directly outside of the patch where the largest concentration 
gradient exists. In the buccal mucosa and submucosa regions, the geometry was subdivided into 
regions such that the regions aligned with the patch had many more elements than those further 
away from the patch. This was done to reduce the computational intensity.  
 
    
(a)     (b) 
Figure 14: a) Mesh for the patch/mucus, buccal mucosa, and submucosa b) Mesh for the patch/mucosa, 
mucosa and submucosal regions. 
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It was important to ensure that our solution is not dependent on the mesh chosen. Mesh 
convergence was assessed qualitatively for two parameters: steady state velocity and initial 
concentration. For steady state flow, the number of elements was increased until a smooth 
velocity profile around the patch edges was obtained. A smooth velocity profile was obtained 
with 40 mesh elements. 
Velocity (Steady state flow) 
         
                    (a)                   (b)                     (c) 
Figure 15: Surface plots of saliva velocity at 3 mesh element values. Velocity profiles are shown for a) 5, 
b) 20, and c) 40 elements in the vertical direction of the mucus layer.  
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Concentration (Mesh convergence evaluated at time t = 0)  
Second, mesh convergence was evaluated for the carvedilol drug concentration at the 
initial time. At this time, the concentration in the patch should be equal to the initial 
concentration, and uniform, with no observable gradient inside the patch. The concentration in 
all tissue layers is initially set to 0. The surface plots of the concentration shown indicated that 
800 elements for the mucus layer was sufficient.   
 
    
              (a)                 (b)                       (c) 
Figure 16: Surface plots of carvedilol concentration as the number of elements is increased. The plots 
showing carvedilol concentration at time 0 a) 40, b) 100 and c) 800 elements in the vertical direction the 
mucus layer. Mesh convergence occurred when the gradient on the patch/mucus boundary was eliminated 
and a clear distinction between the two regions could be made.  
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C. Additional Visuals  
Sensitivity Analysis 
 
Figure 17:  Sensitivity analysis with different mucus diffusivity.  The graph shows that the diffusion of 
drug with time is insensitive to the changes in mucus diffusivity. 
 
 
Figure 18: Sensitivity analysis with different diffusivities of the patch. The graph shows that the 
diffusion of the drug with time is insensitive to the changes in patch diffusivity. 
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Figure 19: Sensitivity analysis with different diffusivities of the mucosa.  The graph shows that the 
changes in mucosa diffusivity does impact the diffusion of drug with time.   
 
 
Figure 20: Sensitivity analysis with different diffusivities of the submucosa layer.  The graph shows that 
the diffusion of the drug with time is insensitive to the changes in submucosa diffusivity. 
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Figure 21: Sensitivity analysis with different saliva/mucus velocity.  The graph shows that the 
diffusion of drug with time is insensitive to the changes in the saliva/mucus velocity.   
 
 
 
Figure 22: The graph shows the sensitivity analysis with different initial concentration of drug in 
the patch.  The data shows that rate of drug diffusion with time is very sensitive to the initial 
concentration of the drug.   
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